These results are supported by findings recently reported by Smith et al., in which use of rapamycin, a PI3K/AKt/mTOR inhibitor, induced terminal differentiation and had anti-proliferative effects in a mouse xenograft model of DD liposarcoma [82]. This evidence concerns the gene AKT1 and liposarcoma.